Epistemic AI, Cincinnati Children’s Hospital Medical Center, and Boomer Esiason Foundation are working together to advance research into the rare disease.
Newly launched life sciences company Sionna Therapeutics has secured funding to fuel discovery and development of drug candidates to treat cystic fibrosis.
The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.
On February 23, five days ahead of the day of rare-disease awareness, OSP’s Rare and Orphan Diseases webinar will share insights from top industry experts.
Vertex was granted marketing authorization for its cystic fibrosis therapy in a combination regimen, marking the company’s third treatment for the condition to reach the market.
Gilead Sciences has received a warning letter from the US Food and Drug Administration (FDA) concerning manufacturing problems at the San Dimas, California, plant, where HIV medicines are made.
Axentis Pharma has received orphan drug designation (ODD) in the US for its cystic fibrosis treatment, which uses liposomes to deliver prolonged high-concentrations of a therapeutic to the infected area.
Researchers claim to have developed a drug delivery system capable of passing through the mucus barrier, which had previously been impenetrable to therapeutics.
Californian pharmaceutical firm Aradigm has unveiled positive
safety and efficacy data from an open-label study of its once daily
inhaled liposomal antibiotic ciprofloxacin in patients with cystic
fibrosis (CF).
The search for novel drug targets for cystic fibrosis received a
boost after Dutch biotechnology company Galapagos announced the
extension of its alliance with Cystic Fibrosis Foundation
Therapeutics (CFFT), the non-profit drug discovery...
Scientists have discovered an unusual distribution of two proteins
in the lungs and airways of people with cystic fibrosis could form
the basis of a therapy that could better define the immune system's
role in cystic fibrosis.
Vertex Pharmaceutcals was one of a number of pharma and biotech
companies to attend the PiperJaffray healthcare conference in
London last week, which gave international companies the
opportunity to provide pipeline updates.
Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation
Therapeutics, (CFFT) have announced they have entered into a
collaboration to develop a novel, oral drug candidate for the
treatment of cystic fibrosis (CF).
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics
have extended their research collaboration initiated in May 2000,
in which CFFT will provide an additional $22 million to further
develop Vertex's therapies that...
Forest Laboratories, having developed what it believes is the
world's first dry powder inhalation system for antibiotics, is now
conducting phase III trials on a new dry powder antibiotic
formulation which promises to change...
US researchers believe they have discovered a new method in
designing a better drug to treat cystic fibrosis - a disease that
currently has no cure. The scientists eventually hope a drug can be
produced that would work efficiently...
An electronic nebuliser that matches a product formulation, which
was specifically developed to optimise this device's performance,
marks a new advance in the customisation of drug development and
represents a new aerosol delivery...
Bayer is to collaborate with Nektar on the development of an
inhaled formulation of Cipro (ciprofloxacin) for treating the
common genetic disorder cystic fibrosis.
Structural GenomiX (SGX) and the Cystic Fibrosis Foundation, have
made a breakthrough in Cystic Fibrosis (CF) research by identifying
the three-dimensional crystal structure of a protein that has been
implicated in the onset of the...
Marcus Mall, from the University of North Carolina in Chapel Hill, genetically modified mice to generate the typical symptoms of CF, something which...
Profile Therapeutics of the UK, a specialist in inhaled therapies,
said it has agreed to supply France's Schering SA with its Prodose
intelligent inhalers to support Schering's product Ventavis
(iloprost), a recently-approved...
Canadian Tm Bioscience introduced its Early Access Program to the
market this week. The programmme is designed to provide testing
labs with pre-commercial access to the company's genetic tests.
